[WEBINAR] Building the Future of Cell based Therapy Trends, Technologies, and Transformations

In this exclusive panel discussion, hosted as part of Genetic Engineering & Biotechnology News’ (GEN) The State of Cell and Gene Therapy 2025 virtual summit, industry leaders explore the key breakthroughs and challenges shaping the future of the field. With recent approvals of MSC, TCR, and TIL therapies in 2024, the panel examines what new milestones 2025 may bring and whether the MSC approval paves the way for broader allogeneic adoption. Experts also discuss the growing shift from viral to non-viral gene editing, the evolving role of CRISPR and iPSC-based therapies, and the persistent challenges of scalability and automation in manufacturing.

Panellists:
Michael Mendicino, Ph.D., President and Owner of Hybrid Concepts International, leads a consulting firm that has supported over 165 clients in the field. With prior experience at the FDA Office of Therapeutic Products and biotech leadership roles, he brings deep regulatory and industry insights.
Derek Hei, Ph.D., Chief Technology Officer at Kenai Therapeutics, has spent over 30 years advancing cell and gene therapies, with a strong focus on iPSC-based therapies.
Jessica Carmen, Ph.D., Chief Commercial Officer at RoslinCT. With over 20 years in the industry, Jessica excels at bridging science and business in cell and gene therapy.
Moderator
Barbara Ressler, Ph.D., VP Manufacturing Process Sciences, with over 20 years of scientific and process development experience in the cell therapy space.

Watch the full recording to gain expert perspectives on the future of the industry: